On November 10, Guardant Health Inc. rose 6.64% in Regular Trading, trading at $160.295 per share, with turnover of $178 million.
The clearest catalyst in recent public disclosures is the company’s third-quarter earnings beat and higher full-year revenue outlook, which helped refocus investors on operating momentum.
Guardant Health Inc. reported adjusted Q3 loss of $0.29 per share, better than market expectations of a $0.31 loss, while revenue rose to $361 million from $265.2 million a year earlier and exceeded expectations of about $350.7 million. The company also lifted full-year revenue guidance to $1.36 billion-$1.37 billion from $1.34 billion-$1.36 billion. Offsetting that, it now expects full-year free cash flow burn of $205 million-$220 million, above its prior outlook of $195 million-$205 million. Recent coverage of the stock’s advance indicated short-term trading was being supported mainly by the revenue beat and improved guidance, despite ongoing litigation-related cost pressure.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments